Buprenorphine Pharmacology Review: Update on Transmucosal and Long-acting Formulations
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Buprenorphine is an effective treatment for opioid use disorder. As a high-affinity, partial agonist for the mu-opioid receptor, buprenorphine suppresses opioid withdrawal and craving, reduces illicit opioid use, and blocks exogenous opioid effects including respiratory depression. Other pharmacologic benefits of buprenorphine are its superior safety profile compared with full opioid agonists and its long half-life that allows daily or less-than-daily dosing. New and innovative buprenorphine formulations, with pharmacokinetic profiles that differ from the original tablet formulation, continue to be developed. These include higher bioavailability transmucosal tablets and films and also 6-month implantable and monthly injectable products. This growing array of available formulations allows more choices for patients and increased opportunity for clinicians to individualize treatment; thus, it is important for buprenorphine prescribers to understand these differences.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
CDC Guideline for Prescribing Opioids for Chronic Pain—United States, 2016
Dowell, D., Haegerich, T. M., & Chou, R. (2016) · JAMA · doi:10.1001/jama.2016.1464 · Cited by 5,161
CDC Guideline for Prescribing Opioids for Chronic Pain — United States, 2016
Dowell, D., Haegerich, T. M., & Chou, R. (2016) · MMWR. Recommendations and Reports · doi:10.15585/mmwr.rr6501e1 · Cited by 2,697 · cited 1×
“While the Centers for Disease Control and Prevention (CDC) Guidelines for Prescribing Opioids for Chronic Pain (Dowell et al., 2016) caution against daily opioid doses >90 MME due to overdose risk, buprenorphine dose escalation does not pose increasing overdose risk like the full opioid agonists due to its low efficac…”
Jasinski, D. R. (1978) · Archives of General Psychiatry · doi:10.1001/archpsyc.1978.01770280111012 · Cited by 782 · cited 2×
“While the abuse potential of buprenorphine is less than that of high-efficacy agonists (Jasinski et al., 1978), it still has intrinsic reinforcing effects as a partial agonist and can be misused and diverted (for review, see Lofwall and Walsh, 2014).”
Clinical pharmacology of buprenorphine: Ceiling effects at high doses
Walsh, S. L., Preston, K. L., Stitzer, M. L., Cone, E. J., & Bigelow, G. E. (1994) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1994.71 · Cited by 773 · cited 2×
“70 to the ethanol/water solution (FDA, 2002) that was used in early buprenorphine studies (Walsh et al., 1994).”
Self-citationUniform assessment and ranking of opioid Mu receptor binding constants for selected opioid drugs
Volpe, D. A., Tobin, G. A. M., Mellon, R. D., Katki, A. G., Parker, R. J., Colatsky, T., Kropp, T. J., & Verbois, S. L. (2011) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2010.12.007 · Cited by 446 · cited 1×
“2 times that of fentanyl, and 120 times that of oxycodone (Volpe et al., 2011).”
Opioid agonist treatments and heroin overdose deaths in Baltimore, Maryland, 1995–2009
Schwartz, R. P., Gryczynski, J., O’Grady, K. E., Sharfstein, J. M., Warren, G., Olsen, Y., Mitchell, S. G., & Jaffe, J. H. (2013) · American Journal of Public Health · doi:10.2105/ajph.2012.301049 · Cited by 276
Middleton, L. S., Nuzzo, P. A., Lofwall, M. R., Moody, D. E., & Walsh, S. L. (2011) · Addiction · doi:10.1111/j.1360-0443.2011.03424.x · Cited by 77
Self-citation
Metadata
- Authors
- Coe, M. A., Lofwall, M. R., & Walsh, S. L.
- Venue
- Journal of Addiction Medicine
- Published
- 2019-03
- Volume
- 13
- Issue
- 2
- Pages
- 93-103
- ISSN
- 1932-0620 (ISSN-L)
- 1935-3227
- OpenAlex
- W2898561048
- Cited by
- 173
- References
- 7
- FWCI
- 9.91
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Buprenorphine Pharmacology Review: Update on Transmucosal and Long-acting Formulations. https://app.cochat.ai/papers/10.1097/adm.0000000000000457
- The paper
- Coe, M. A., Lofwall, M. R., & Walsh, S. L. (2019). Buprenorphine Pharmacology Review: Update on Transmucosal and Long-acting Formulations. Journal of Addiction Medicine. https://doi.org/10.1097/adm.0000000000000457
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.